Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flavopyridol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 known ✓ | P24941 | 14/20 | 1.00 |
| ▸ | CDK4 known ✓ | P11802 | 12/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 11/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 10/20 | 1.00 |
| ▸ | CDK7 known ✓ | P50613 | 3/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 2/20 | 1.00 |
| ▸ | CCND1 | P24385 | 11/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 9/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 9/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 8/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 6/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 6/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvocidib SCHEMBL5868074 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29388553 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29351027 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29577824 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL12445809 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL16927354 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL3652 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL8214028 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL3651 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL28199338 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361485-A1 | MODIFIED CD4+ T CELLS EXPRESSING IL-37 AND METHODS OF USE THEREOF | UNIV COLORADO REGENTS (US) | 2025-11-27 | — | — | US | disclosed |
| US-12466819-B2 | Tricyclic compounds with OMA1/OPA1 modulatory properties | 712 NORTH INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4558620-A1 | MODIFIED CD4+ T CELLS EXPRESSING IL-37 AND METHODS OF USE THEREOF | The Regents of the University of Colorado, a body corporate (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024249554-A1 | MULTITARGET SMALL MOLECULE INHIBITORS AND USES THEREOF | THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY D/B/A ATRIUM HEALTH (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024020413-A1 | MODIFIED CD4+ T CELLS EXPRESSING IL-37 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230165827-A1 | ISOTHIOCYANATE FUNCTIONAL COMPOUNDS AUGMENTED WITH SECONDARY ANTINEOPLASTIC MEDICAMENTS AND ASSOCIATED METHODS FOR TREATING NEOPLASMS | THE WILLIAM M YARBROUGH FOUND (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165827-A1 | ISOTHIOCYANATE FUNCTIONAL COMPOUNDS AUGMENTED WITH SECONDARY ANTINEOPLASTIC MEDICAMENTS AND ASSOCIATED METHODS FOR TREATING NEOPLASMS | THE WILLIAM M YARBROUGH FOUND (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230065809-A1 | TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES | 712 NORTH INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20210137841-A1 | SUSTAINED RELEASE FORMULATIONS OF DYSOXYLUM BINEFACTERUM | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-05-13 | — | — | US | disclosed |
| WO-2020213714-A1 | METHOD FOR PRODUCING CIS-(-)-FLUOCINO PIPERIDOL | 大日本住友製薬株式会社 | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137841-A1 | SUSTAINED RELEASE FORMULATIONS OF DYSOXYLUM BINEFACTERUM | CRH, SYMPK, MDK | CDK2 1070/4885CDK4 913/4885CDK1 854/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | CDK2 4213/4885CDK4 4148/4885CDK1 3881/4885 |
| US-20230065809-A1 | TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES | OPA1, OLA1, ACOX1 | CDK2 2237/4885CDK4 1563/4885CDK1 1345/4885 |
| US-12466819-B2 | Tricyclic compounds with OMA1/OPA1 modulatory properties | OPA1, OLA1, ACOX1 | CDK2 2237/4885CDK4 1563/4885CDK1 1345/4885 |
| US-20230165827-A1 | ISOTHIOCYANATE FUNCTIONAL COMPOUNDS AUGMENTED WITH SECONDARY ANTINEOPLASTIC MEDICAMENTS AND ASSOCIATED METHODS FOR TREATING NEOPLASMS | TP53, GSTA2, GSTA1 | CDK2 1096/4885CDK4 1018/4885CDK1 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.